Literature DB >> 16860974

Characteristics of two alternative schizophrenia remission definitions: relationship to clinical and quality of life outcomes.

Eduardo Dunayevich1, Gopalan Sethuraman, Mark Enerson, Cindy C Taylor, Daniel Lin.   

Abstract

BACKGROUND: The goal of these secondary analyses of clinical trial data was to characterize clinical outcomes in patients with schizophrenia who met symptom severity or duration thresholds for two alternative definitions of remission, and to explore their relationships to improvement duration and quality of life outcomes.
METHODS: Definition 1 used threshold criteria for selected PANSS items sustained over at least 6-months Definition 2 used Brief Psychiatric Rating Scale (BPRS) % change, a threshold score for the Clinical Global Improvement-Severity (CGI-S) maintained for at least 8 weeks, and threshold scores for selected BPRS items. Positive and Negative Symptom Scale (PANSS) and Quality of Life scale (QLS) total scores were pooled from 6 clinical trials. The extent to which the alternative severity thresholds from these two definitions and duration of clinical improvement were associated with different clinical and QLS outcomes was explored. Regression analysis also assessed the relative contribution of each of the components of the two definition severity thresholds to improvements in QLS Total score.
RESULTS: Increases in QLS scores were greater for those patients who met either threshold criteria relative to those who met neither (p<.0001). Significantly greater improvements in QLS scores were observed for patients who met either threshold criteria at the 8-, 16- and 24-week visits relative to those who met criteria at weeks 16 and 24, or at week 24 only (p<0.001), as well as for the subset of patients who met threshold criteria at both 24 and 52 weeks relative to those who met criteria at only one of these 2 time points. Only 31% to 47% of patients meeting threshold criteria for either definition at the 8-, 16- or 24-week visits remained in remission at the 52-week visit. Among the severity threshold components analyzed, BPRS total % change from baseline was the strongest predictor of improvement in QLS scores.
CONCLUSIONS: Quality of life improved most for patients who achieved severity thresholds associated with either remission criteria and who stayed improved for longer periods. Total BPRS change scores accounted for the greatest percentage of the QLS scores variance. Only a fraction of patients who meet severity criteria for either remission definition early in treatment will remain at that level of improvement within the subsequent 9-12 months.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16860974     DOI: 10.1016/j.schres.2006.06.002

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  11 in total

1.  Remission in schizophrenia: the relationship to baseline symptoms and changes in symptom domains during a one-year study.

Authors:  D L Kelly; E Weiner; M P Ball; R P McMahon; W T Carpenter; R W Buchanan
Journal:  J Psychopharmacol       Date:  2008-06-26       Impact factor: 4.153

2.  What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial.

Authors:  Rebecca Schennach; Michael Riedel; Michael Obermeier; Ilja Spellmann; Richard Musil; Markus Jäger; Max Schmauss; Gerd Laux; Herbert Pfeiffer; Dieter Naber; Lutz G Schmidt; Wolfgang Gaebel; Joachim Klosterkötter; Isabella Heuser; Wolfgang Maier; Matthias R Lemke; Eckart Rüther; Stefan Klingberg; Markus Gastpar; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-09-27       Impact factor: 5.270

3.  Rates and correlations of change in three dimensions of recovery within a recovery model oriented therapeutic community.

Authors:  Matt Snyder; Lisa Schactman; Sharon Young
Journal:  Psychiatr Q       Date:  2015-03

4.  Shared and distinct alterations of white matter tracts in remitted and nonremitted patients with schizophrenia.

Authors:  Jing-Ying Huang; Chih-Min Liu; Tzung-Jeng Hwang; Yu-Jen Chen; Yung-Chin Hsu; Hai-Gwo Hwu; Yi-Tin Lin; Ming-Hsien Hsieh; Chen-Chung Liu; Yi-Ling Chien; Wen-Yih Isaac Tseng
Journal:  Hum Brain Mapp       Date:  2018-01-28       Impact factor: 5.038

5.  The SWITCH study: rationale and design of the trial.

Authors:  Stephan Heres; Diana Meliu Cirjaliu; Liana Dehelean; Valentin Petre Matei; Delia Marina Podea; Dorina Sima; Lynne Stecher; Stefan Leucht
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-07-31       Impact factor: 5.270

6.  Defining the minimal clinically important difference (MCID) of the Heinrichs-carpenter quality of life scale (QLS).

Authors:  Bruno Falissard; Christophe Sapin; Jean-Yves Loze; Wally Landsberg; Karina Hansen
Journal:  Int J Methods Psychiatr Res       Date:  2015-08-04       Impact factor: 4.035

7.  Long-term remission in schizophrenia and schizoaffective disorder: results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE).

Authors:  Enrico Smeraldi; Roberto Cavallaro; Vera Folnegović-Šmalc; Leszek Bidzan; Mehmet Emin Ceylan; Andreas Schreiner
Journal:  Ther Adv Psychopharmacol       Date:  2013-08

Review 8.  Remission in schizophrenia: validity, frequency, predictors, and patients' perspective 5 years later.

Authors:  Martin Lambert; Anne Karow; Stefan Leucht; Benno G Schimmelmann; Dieter Naber
Journal:  Dialogues Clin Neurosci       Date:  2010       Impact factor: 5.986

9.  Proposed criteria for schizophrenia remission.

Authors:  Bandar Alaqeel
Journal:  Neuropsychiatr Dis Treat       Date:  2014-04-16       Impact factor: 2.570

10.  Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational study.

Authors:  Virginia S Haynes; Baojin Zhu; Virginia L Stauffer; Bruce J Kinon; Michael D Stensland; Lei Xu; Haya Ascher-Svanum
Journal:  BMC Psychiatry       Date:  2012-12-05       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.